Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 9,542,292
  • Shares Outstanding, K 60,090
  • Annual Sales, $ 1,488 M
  • Annual Income, $ 396,830 K
  • 36-Month Beta 1.10
  • Price/Sales 6.44
  • Price/Cash Flow 17.93
  • Price/Book 4.82

Price Performance

See More
Period Period Low Period High Performance
1-Month
144.91 +9.59%
on 06/06/17
160.00 -0.75%
on 06/23/17
+8.19 (+5.44%)
since 05/23/17
3-Month
139.72 +13.66%
on 04/05/17
163.75 -3.02%
on 04/28/17
+16.30 (+11.44%)
since 03/23/17
52-Week
95.80 +65.76%
on 11/04/16
163.75 -3.02%
on 04/28/17
+13.80 (+9.52%)
since 06/23/16

Most Recent Stories

More News
After Yesterday's Rally of 2.04% Shares Could Potentially Pullback

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $152.02 to a high of $155.82. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day...

JAZZ : 158.80 (-0.43%)
Jazz Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.11%

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $146.54 to a high of $149.76. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low...

JAZZ : 158.80 (-0.43%)
Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?

Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ : 158.80 (-0.43%)
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 3.96% Gain

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $146.10 to a high of $152.78. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day...

JAZZ : 158.80 (-0.43%)
Jazz Pharma Sleep Disorder Candidate Positive in Phase III

Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy...

JAZZ : 158.80 (-0.43%)
VVUS : 1.22 (+5.17%)
ZTS : 62.78 (-1.15%)
NVS : 86.34 (unch)
Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea

Data were presented in a poster presentation at the annual SLEEP Meeting; JZP-110 U.S. NDA submission planned for later this year

JAZZ : 158.80 (-0.43%)
Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented positive efficacy results from its global multicenter studies (TONES 3 and TONES 4) of JZP-110 in adult patients with excessive sleepiness associated...

JAZZ : 158.80 (-0.43%)
Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented the positive efficacy results from its global multicenter study of JZP-110 in adult patients with excessive sleepiness associated with narcolepsy....

JAZZ : 158.80 (-0.43%)
Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review

Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.

AGIO : 59.18 (+3.07%)
CELG : 134.31 (+0.47%)
JAZZ : 158.80 (-0.43%)
GLYC : 13.41 (+10.83%)
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS(TM) (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for VYXEOS(TM)...

JAZZ : 158.80 (-0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Support & Resistance

2nd Resistance Point 162.69
1st Resistance Point 160.74
Last Price 158.80
1st Support Level 156.11
2nd Support Level 153.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.